Gapping up
In reaction to earnings/guidance:
- TBI +12.7%, CROX +8.1%, WIRE +7.7%, UPS +7.1%, AAN +6.3%, EBIX +4.8%, AUDC +4.6%, ADM +4.6%, HSTM +4.5%, BRO +4.4%, SSD +4.1%, OMF +3.6% (also to acquire Trim; also raises dividend and commences new buyback program), CATY +3.5%, HSBC +3.5%, MKSI +3.3%, SSNC +3.2%, PKG +3.2%, HUBB +2.9%, TPB +2.9%, SBAC +2.8%, LU +2.5%, MMC +2%, BP +1.9%, SSTK +1.9%, RRC +1.8%, ROP +1.8%, HEES +1.8%, PPBI +1.7%, MSCI +1.6%, JBLU +1.5%, FISV +1.5%, WM +1.5%, SUI +1.4%, AMKR +1.3%, AGNC +1.3%, ABB +1.3%, RTX +1.3%, SYF +1.1%, NXPI +1%
Other news:
- ALDX +25.2% (announces "positive" top-line results from the Phase 3 INVIGORATE Clinical Trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis)
- FCBP +21.1% (EFSC to acquire FCBP in all-stock merger agreement)
- GME +11.5% (completes previously announced at-the-market equity offering program)
- LOGC +10% (announces strategic collaboration with CANbridge Pharmaceutical and research collaboration with Daiichi Sankyo (DSNKY); provides update on SUNRISE enrollment)
- LYFT +2.8% (LYFT to sell self-driving car division to Toyota (TM) subsidiary Woven Planet for $550 mln)
- CGEN +2.6% (announced the publication of a peer-reviewed article in Cancer Immunology, Immunotherapy)
- AKTS +2.6% (announced the issuance of nine new patents)
- RETA +2.4% (announces FDA acceptance for filing of NDA for bardoxolone methyl as treatment for CKD)
- CHDN +2.3% (launches TwinSpires Sports mobile app in three states)
- RMBS +1.8% (RMBS and LSCC announce partnership on next-generation security solutions)
- NBIX +1.3% (enters into research collaboration with Sentia Medical)
Analyst comments:
- GLOP +5.2% (upgraded to Buy from Hold at Jefferies)
- SYNA +2.7% (upgraded to Outperform from Market Perform at Cowen)
- SCHW +1.9% (upgraded to Outperform from Neutral at Credit Suisse)